Allergy Therapeutics plc has disclosed a Form 8.5 (EPT/RI) from Panmure Gordon (UK) Limited, an exempt principal trader with recognized intermediary status. The form provides key information regarding dealings in Allergy Therapeutics' securities. The date of dealing was October 24, 2023. The form includes details of purchases and sales of the company's 0.1p ordinary shares, with the highest price per unit paid/received at 0.013375 and the lowest price per unit paid/received at the same value. The form also mentions cash-settled derivative transactions and stock-settled derivative transactions, but no specific details are provided.
The form further states that there are no indemnity or option arrangements, agreements, or understandings relating to relevant securities that may be an inducement to deal or refrain from dealing. Similarly, there are no agreements, arrangements, or understandings relating to options or derivatives. The contact person for this disclosure is Freddie Wooding, and the date of disclosure is October 25, 2023.
No further information or details about Allergy Therapeutics or its operations are provided in this news release.